Shanghai, November 3 (Xinhua) - Boston Scientific, a US funded medical device company, recently announced two news in Shanghai. Firstly, its first production and manufacturing base in China has been built and opened in Lingang, Shanghai, which will serve the needs of local doctors and patients in China with a more agile and resilient supply chain; The second is to bring more than 80 cutting-edge medical technologies and products to participate in the 7th China International Import Expo, of which 5 will soon be launched in China through the CIIE platform.
It is reported that the Shanghai Lingang Base, as an important component of Boston Scientific's comprehensive localization strategy layout in China, will focus on the production of medical consumables and equipment with "leading technology and domestic intelligent manufacturing", covering the entire industry chain of trade, production, research and development, investment, and services. More than 80 cutting-edge medical technologies and products participated in the 7th CIIE, covering multiple fields such as heart, peripheral blood vessels, tumors, urology, digestion, and neural regulation that Boston Scientific excels in. Among them, the new generation intravascular ultrasound system is an innovative product with artificial intelligence characteristics. The Chinese R&D team has deeply participated in the related software and hardware research and development, and the core host is produced in China. It is not only the latest representative of Boston Scientific's local R&D and production, but also the "first release" in the Chinese market.
Zhang Jun, President of Boston Scientific Greater China, stated that the above two messages clearly demonstrate the confidence and direction of Boston Scientific's development in China, namely accelerating its transition from exhibitors to investors, increasing investment in the Chinese market, and growing together with the Chinese healthcare industry.
She said that this year marks the sixth consecutive year that Boston Science has participated in the CIIE. Every time we participate in the exhibition, we can strongly feel the enthusiasm and thirst of the Chinese market for cutting-edge medical innovation, and it is also a good opportunity for learning and exchange. "We have thus clarified what we should do in the Chinese market.
Statistics show that since its first participation in the CIIE in 2019, Boston Scientific has accumulated 21 innovative achievements that have transformed from exhibits to products, accelerating their listing in China. Since last year's CIIE alone, 9 innovative exhibits have been approved for listing in China. In sync with numerous innovative exhibits and accelerated technology launches, Boston Scientific's business in China has maintained double-digit growth in recent years.
Taking a hot steam therapy system for treating benign prostatic hyperplasia as an example, it was launched two and a half years earlier than the traditional pathway. In just one year, more than 5000 patients with benign prostatic hyperplasia in China have bid farewell to traditional gland resection surgery and received safer, more convenient, and efficient medical services. The acceleration and spillover effects of the CIIE are very obvious.
At the 7th CIIE, Boston Scientific will set up a neural regulation exhibition area for the first time, showcasing innovative medical solutions for managing chronic pain and treating Parkinson's disease. In the field of digestive health, Boston Scientific will focus on showcasing an innovative surgical treatment plan for adult obese individuals, which involves sleeve shaped shaping of the stomach under endoscopy, gradually reducing the volume of the stomach and achieving weight loss. This non-surgical surgery not only preserves the patient's organs but also has reversibility, providing more options for weight loss treatment.
Zhang Jun believes that it is the good effect of participating in the CIIE for years that has strengthened the confidence of Boston Scientific Headquarters in the Chinese market and made the decision to invest in the construction of the Shanghai Lingang Base. As a medical device company with a history of 45 years, Boston Scientific's judgment is that the Chinese market not only cannot be left, but also needs to increase investment.
Zhang Jun stated that the CIIE carries the grand vision of sharing China's opportunities with the world and promoting innovation between China and the world. As a permanent guest and beneficiary of the CIIE, Boston Scientific Future will share global innovation and management experience with Chinese partners in various aspects such as commercial licensing, R&D co creation, and compliance and systematic management empowerment through majority equity investment and strategic cooperation in China, promoting the extension of China's medical industry upstream of the global value chain and benefiting global patients with Chinese innovation.